These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33181577)

  • 1. DEA Disconnect Leads to Buprenorphine Bottlenecks.
    Ostrach B; Carpenter D; Cote LP
    J Addict Med; 2021 Jul-Aug 01; 15(4):272-275. PubMed ID: 33181577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.
    Ostrach B; Hill L; Carpenter D; Pollini R
    J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.
    Jones KF; O'Reilly Jacob M; Spetz J; Hailer L; Tierney M
    J Nurs Scholarsh; 2023 May; 55(3):655-664. PubMed ID: 36624606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky.
    Cooper HL; Cloud DH; Freeman PR; Fadanelli M; Green T; Van Meter C; Beane S; Ibragimov U; Young AM
    Int J Drug Policy; 2020 Nov; 85():102701. PubMed ID: 32223985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What the X? Understanding changes in buprenorphine prescribing regulation.
    Speight C
    J Am Assoc Nurse Pract; 2024 Mar; 36(3):147-150. PubMed ID: 37646580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
    Ostrach B; Potter R; Wilson CG; Carpenter D
    J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors in rural community buprenorphine dispensing.
    Major EG; Wilson CG; Carpenter DM; Harless JC; Marley GT; Ostrach B
    Explor Res Clin Soc Pharm; 2023 Mar; 9():100204. PubMed ID: 36703716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act.
    Adams JA; Chopski NL; Adams AJ
    J Am Pharm Assoc (2003); 2023; 63(5):1495-1499. PubMed ID: 37295494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.
    Hill LG; Light AE; Green TC; Burns AL; Sanaty Zadeh P; Freeman PR
    J Am Pharm Assoc (2003); 2023; 63(1):252-260.e6. PubMed ID: 36202711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
    Textor L; Ventricelli D; Aronowitz SV
    Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.
    Abell-Hart K; Rashidian S; Teng D; Rosenthal RN; Wang F
    JMIR Public Health Surveill; 2022 Apr; 8(4):e32133. PubMed ID: 35412467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021.
    Larochelle MR; Jones CM; Zhang K
    Drug Alcohol Depend; 2023 Jul; 248():109933. PubMed ID: 37267746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.